Mirae Asset Global ETFs Holdings’s Arcutis Biotherapeutics ARQT Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.49M	Buy	94,638 +6,154	+7%	+$143K	﹤0.01%	1140
2026 Q1	$2.06M	Buy	88,484 +4	+0%	+$102	﹤0.01%	1157
2025 Q4	$2.56M	Sell	88,480 -7,145	-7%	-$183K	﹤0.01%	1044
2025 Q3	$1.8M	Buy	95,625 +29,389	+44%	+$463K	﹤0.01%	1186
2025 Q2	$927K	Sell	66,236 -5,181	-7%	-$72.6K	﹤0.01%	1481
2025 Q1	$1.12M	Buy	71,417 +2,063	+3%	+$29.1K	﹤0.01%	1446
2024 Q4	$968K	Sell	69,354 -15	-0%	-$164	﹤0.01%	1561
2024 Q3	$646K	Buy	69,369 +18,925	+38%	+$187K	﹤0.01%	1789
2024 Q2	$470K	Buy	+50,444	New	+$456K	﹤0.01%	1855

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's ARQT Position: Q2 2026 in Review

Mirae Asset Global ETFs Holdings increased its Arcutis Biotherapeutics (ARQT) stake by 7% in Q2 2026, buying an estimated $143K and bringing the position to 94,638 shares worth $2.49M. The position accounts for ﹤0.01% of the portfolio, ranked #1140.

Mirae Asset Global ETFs Holdings first reported a position in ARQT in Q2 2024 and has held it in 9 quarters since. The position peaked at $2.56M in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

Mirae Asset Global ETFs Holdings held 94,638 shares of Arcutis Biotherapeutics worth $2.49M as of Q2 2026.
Mirae Asset Global ETFs Holdings bought 6,154 Arcutis Biotherapeutics shares in Q2 2026, an estimated $143K.
Arcutis Biotherapeutics made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q2 2026, its #1140 holding.
Mirae Asset Global ETFs Holdings first reported a position in Arcutis Biotherapeutics in Q2 2024 and has held it in 9 quarters since.
Mirae Asset Global ETFs Holdings's Arcutis Biotherapeutics position peaked at $2.56M in Q4 2025.
272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.